EUCAST Technical Note on fluconazole
Author:
European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). Rodriquez Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning D, Fegeler W, Gaustad P, Klimko N, Lass-Flörl C, Moore C, Richardson M, Schmalreck A, Stenderup J, Velegraki A, Verweij P
Date: 4 March 2008
Abstract:
Fluconazole is an azole antifungal agent active against Candida spp. and Cryptococcus spp. It can be administered orally or intravenously. It has been used for treating Candida infections, and is effective in treating infections caused by strains of Candida albicans, Candida tropicalis and Candida parapsilosis without acquired resistance mechanisms. The drug is ineffective for treating infections caused by Candida krusei, which is naturally resistant. The response of infections caused by Candida glabrata is variable, as the wild-type MIC distribution straddles most reasonable MIC breakpoints. Every attempt should be made to identify Candida isolates to the species level before or in conjunction with antimicrobial susceptibility testing. The EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing—Subcommittee on Antifungal Susceptibility Testing) has determined breakpoints of fluconazole for Candida spp. This Technical Note is based on the EUCAST fluconazole rationale document (available on the EUCAST website: http://www. eucast.org). The rationale document includes more detail and published references related to the selection of EUCAST-AFST breakpoints.
Download the full article (Disclaimer)
This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.